1. Lamb DS, Spry NA, Gray AJ, Johnson AD, Alexander SR, Dally MJ. Accelerated fractionation radiotherapy for advanced head and neck cancer. Radiother. Oncol. 1990; 18: 107-116. Abstract
   
2. Gill PG, Denham JW, Jamieson GG, Devitt PH, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J. Clin. Oncol. 1992; 10: 1037-1043. Abstract
   
3. Hamilton CS, Denham JW, Joseph DJ, et al. Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian patterns of practice study. Clin. Oncol. 1992; 4: 141-147. Abstract
   
4. Hamilton CS and Denham JW. Dose normalisation and specification: from woe to go. Australas. Radiol. 1992; 36: 137-141. Abstract
   
5. Denham JW, Hamilton CS, Joseph DJ, et al. The use of simulator and CT information in the planning of radiotherapy for non-small cell lung carcinoma; an Australasian patterns of practice study. Lung Cancer. 1993; 8: 275-284. Abstract
   
6. Atkinson CH, Hamilton CS, Wynne CJ. Radiotherapy planning for lung cancer: Can we do better? Australas. Radiol. 1994; 38: 303-304. Abstract
   
7. Denham JW. Oesophageal cancer - guarded optimism. Med. J. Aust. 1994; 160: 669-670.
   
8. Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicentre study. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32: 997-1006. Abstract
   
9. Denham JW, Hamilton CS, Christie D, O'Brien M, Bonaventura A, Stewart JF et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer - toxicity and dose modification: a Trans-Tasman Radiation Oncology Group multi-institution study. Int. J. Radiat. Oncol. Biol. Phys. 1995; 31: 305-313. Abstract
   
10. Christie DRH, O'Brien MY, Christie JA, Kron T, Ferguson SA, Hamilton CS et al. A comparison of methods of cosmetic assessment in breast conservation treatment. Breast. 1996; 5: 358-367. Abstract
    
11. Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS et al. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother. Oncol. 1996; 40: 31-43. Abstract
    
12. Denham JW, Walker QJ, Lamb DS, Hamilton CS, O'Brien PC, Spry NA et al. Mucosal regeneration during radiotherapy. Radiother. Oncol. 1996; 41: 109-118. Abstract
    
13. MacKean J, Burmeister BH, Lamb DS, Denham JW. Concurrent chemo-radiation for oesophageal cancer - Factors influencing myelotoxicity. Australas. Radiol. 1996; 40: 424-429. Abstract
    
14. O'Brien PC, Roos D, Liew K-H, Trotter G, Barton M, Walker Q et al. Preliminary results of combined modality therapy for non-AIDS primary CNS lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med. J. Aust. 1996; 165: 424-427. Abstract
    
15. Denham J and on behalf of the Trans-Tasman Radiation Oncology Group (TROG). Response to L. R. Coia re factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother. Oncol. 1997; 42: 91-92.
    
16. O’Brien PC, Franklin CI, Dear KBG, Hamilton CS, et al. A phase III doubl-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis: Trans-Tasman Radiation Oncology Group (TROG). Radiother. Oncol. 1997; 45(2): 117 – 123. Abstract
    
17. Smithers BM, Devitt P, Jamieson GG, Bessell J, Gotley D, Gill PG et al. A combined modality approach to the management of oesophageal cancer. Eur. J. Surg. 1997; 23: 219-223. Abstract
    
18. Hamilton CS, Walker Q, Poulsen M, Spry N, Lamb D, Denham JW et al. Quality Assurance Audit in an Australasian Phase III Trial of Accelerated Radiotherapy for Head and Neck Cancer (TROG 91. 01). Australas. Radiol. 1999; 43: 227-232. Abstract
    
19. Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother. Oncol. 1999; 52: 157-164. Abstract
    
20. Denham JW, Atkinson C, on behalf of the Trans-Tasman Radiation Oncology Group (TROG). Where is your evidence? Australas. Radiol. 1999; 43: 124-125.
    
21. Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas. Radiol. 1999; 43: 220-226. Abstract
    
22. Poulsen M, Denham JW, Spry N, Lamb D, Peters L, Williamson S et al. Acute toxicity analysis of a phase III randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the upper aero digestive tract: A Trans-Tasman Radiation Oncology Group Study. Australas. Radiol. 1999; 43: 487-494. Abstract
    
23. Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P et al. Causes for increased myelosuppression with increasing age in patients with esophageal cancer treated by chemo-radiation. Eur. J. Cancer. 1999; 35: 921-927. Abstract
    
24. Lamb DS, Denham JW, Morum PE, Gray AJ. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II study. Radiother. Oncol. 1998; 49: 29-32. Abstract
    
25. Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I et al. A quality assurance audit: Phase III trial of maximal androgen deprivation in prostate cancer (TROG 96. 01). Australas. Radiol. 2000; 44: 65-71. Abstract
    
26. Roos DE, Davis SR, O'Brien PC, Hoskin PJ, Spry NA, Burmeister BH et al. Eligibility audits for the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group Study, TROG 96. 05). Australas. Radiol. 2000; 44: 303-307. Abstract
    
27. Roos DE, O'Brien PC, Smith JG, Spry NA, Hoskin PJ, Burmeister BH et al. A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96. 05). Int. J. Radiat. Oncol. Biol. Phys. 2000; 46: 975-981. Abstract
    
28. O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 2000; 18: 519-526.
    
29. Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study (TROG 91. 01). Radiother. Oncol. 2001; 60: 113-122. Abstract
    
30. Ngan SYK, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A et al. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A phase II trial for the Trans-Tasman Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 883-887. Abstract
    
31. Poulsen M, Rischin D, Walpole E, Harvey J, Macintosh J, Ainslie J et al. Analysis of toxicity of Merkel Cell Carcinoma of the skin treated with synchronous carboplatin/etopside and radiation: A Trans-Tasman Radiation Oncology Group study - TROG 96. 07. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 156-163. Abstract
    
32. Burmeister BH, Smithers BM, Davis S, Spry N, Johnson C Krawitz H, Baumann KC. Radiation therapy following nodal surgery for melanoma: An analysis of late toxicity. ANZ J. Surg. 2002; 72: 344 – 348. Abstract
    
33. Kron T, Hamilton C, Roff M, Denham JW. Dosimetric intercomparison for two Australasian clinical trials using ananthropomorphic phantom. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52(2): 566 – 579. Abstract
    
34. Denham JW and Kron T. Extinction of the weakest. Int J Radiat Oncol Biol Phys. 2001; 51(3): 807 – 819. Abstract
    
35. O'Brien PC, Franklin CI, Joseph DJ, Spry NS, Denham JW. Acute symptoms, not rectally administered Sucralfate, predict for late radiation proctitis. Longer-term follow-up of a Phase 3 trial – Trans-Tasman Radiation Oncology Group (TROG). Int.J.Radiat.Oncol.Biol.Phys. 2002; 54(2): 442 – 449. Abstract
    
36. Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, et al. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clinical Oncology. 2003; 15: 98 – 108. Abstract
    
37. Roos DE, Davis SR, Turner SL, O’Brien PC, Spry NA, Burmeister BH, Hoskin PJ and Ball DL. Quality assurance experience with the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05). Radiotherapy and Oncology. 2003; 67: 207 – 212. Abstract
    
38. Daly T, Poulsen GM, Denham JW, Peters LJ, Lamb DS, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology. 2003; 68: 113 – 122. Abstract
    
39. Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiotherapy and Oncology. 2003; 68: 255 – 267. Abstract
    
40. Bydder S, Spry NA, Christie DRH, Roos D, Burmeister BH, Krawitz H, Davis S, Joseph DJ, Poulsen M, Berry M. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australasian Radiology. 2003; 47: 284 – 288. Abstract
    
41. Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, Hamilton C, Keller J, Tripcony L. High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07. Journal of Clinical Oncology. 2003; Vol 21, No 23: 4371-4376. Abstract
42. Christie D, Sharpley C, Curtis T. Improving the Accuracy of a Photographic Assessment System for Breast Cosmesis. Clinical Oncology 2005; 17, 27-31 Abstract
43. D.E. Roos, S.L. Turner, P.C. O'Brien, J.G. Smith, N.A. Spry, B.H. Burmeister, P.J. Hoskin, D.L. Ball Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiotherapy and Oncology Volume: 75 Issue: 1 Date: Apr-2005 Abstract
44. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans Tasman Radiation Oncology Group (TROG 98.02) Journal of Clinical Oncology. 2005 Vol 23, No. 1: 79-87 Abstract
45. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology 2005; 6:659-68 Abstract  
46. Pollicino CA, Turner SL, Roos DE, O’Brien PC. Costing the components of pain management. Analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): One versus five fractions for neuropathic bone pain. Radiotherapy and Oncology 76 (2005) 264 – 269 Abstract
47. Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Spry N, Tai K, Wynne C, Duchesne G, Kovacev O, Francis L, Kramar A, D’Este C, Bill D. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiotherapy and Oncology 77 (2005) 117-125 Abstract
48. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai K-H, Wynne C, Duchesne G, Kovacev O, D’Este C. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncology 2005;6:841-50 Abstract
49. Ngan SYK, Fisher R, Burmeister BH, Mackay J, Goldstein D, Kneebone A, Schache D, Joseph D, McKendrick J, Leong T, McClure B, Rischin D. Promising results of a co-operative group phase II trials of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Diseases of Colon and Rectum 2005,48:1389-96.Abstract
50. Graham PH, Capp A, Delaney G, Goozee G, Hickey B, Turner S, Browne L, Milross C, Wirth A. A pilot randomised comparison of Dexamethasone 96 mg versus 16mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex Study. Clinical Oncology (2006) 18: 70-76. Abstract
51. Poulsen M, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, Keller J, Tripcony L.  Does Chemotherapy improve survival in high risk stage I and II Merkel Cell Carcinoma of the skin? Int. J. Radiation Oncology Biol. Phys. 64, 1, 114-119, 2006. Abstract
52. O’Brien PC, Roos DE, Pratt G, Liew K-H, Barton MB, Poulsen MG, Olver IA, Trotter GE. Combined-modality Therapy for Primary Central Nervous System Lymphoma: Long-term Data from a Phase II Multi-center Study (Trans-Tasman Radiation Oncology Group). Int. J. Radiation Oncology Biol. Phys., 64, 2, 408-413, 2006. Abstract
53. Chow E, Hoskin P, Wuz J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A Phase III International Randomised Trial Comparing Single with Multiple Fractions for Re-irradiation of Painful Bone Metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. Clinical Onoclogy, vol 18, no. 2, 125-128, 2006. (Editorial) Abstract
54. Chen Y, Trotti A, Coleman CN, Machtay M, Mirimanoff RO, Hay J,  O’Brien PC, El-Gueddari B,  Salvajoli JV, Jeremic B. Adverse Event Reporting And Developments In Radiation Biology After Normal Tissue Injury: International Atomic Energy Agency Consultation. Int. J. Radiation Oncology Biol. Phys., Vol. 64, No. 5, pp. 1442–1451, 2006. Abstract
55. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S and Peters LJ. Prognostic significance of [F-18]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02. Journal of Clinical Oncology. Vol 24, No. 13, pp. 2098-2104, 2006. Abstract
56. Ball DL, Fisher R, Burmeister B, Graham P, Joseph D, Penniment M, Krawitz H, Wheeler G, Poulsen M, Vinod S and McClure B. Stage Is Not a Reliable Indicator of Tumor Volume in Non-small Cell Lung Cancer: A Preliminary Analysis of the Trans-Tasman Radiation Oncology Group 99-05 Database. Journal of Thoracic Oncology: Volume 1(7) September 2006 pp 667-672. Abstract
57. Roos D, Wirth A, Burmeister B, Spry N, Drummond K, Beresford J and McClure B. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiotherapy and Oncology 80 (2006) 318-322. Abstract
58. Gogna N, Matthews J, Turner S, Mameghand H, Duchesne G, Spry N, Berry M, Keller J and Tripcony L. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiotherapy and Oncology 81 (2006) 9–17. Abstract
59. Burmeister  B. Smithers M,  Burmeister E, Baumann K, Davis S, Krawitz H, Johnson C and Spry N. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma -Trans Tasman Radiation Oncology Group (TROG) study  96.06. Radiotherapy and Oncology 81 (2006) 136–142. Abstract

[ Publications & News - Home ]